Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis

53Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.
Get full text

Abstract

This study investigated the delivery of a model therapeutic protein, namely, osteoprotegerin (OPG), to bone sites in an animal model of osteoarthritis. The OPG was chemically conjugated to a "bone seeking" thiol-bisphosphonate (thiolBP) via a disulfide linkage. The BP conjugates of OPG were shown to display a higher hydroxyapatite affinity in vitro as compared to unmodified OPG. After intravenous injection, the bone uptake of OPG-thiolBP conjugate was increased 2-fold over that of control OPG under conditions of normal bone turnover. Furthermore, the retention of the OPG-thiolBP conjugate was significantly higher after 72 h. When administered to osteoarthritic rats undergoing active bone remodeling, the delivery of OPG-thiolBP conjugate to bone was increased more than 4-fold over that of control OPG after 24 h. These results suggest a significant advantage of BP conjugation as a drug delivery strategy for therapeutic cytokines in osteopenic bone diseases. © 2009 American Chemical Society.

Cite

CITATION STYLE

APA

Doschak, M. R., Kucharski, C. M., Wright, J. E. I., Zernicke, R. F., & Uludag, H. (2009). Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis. Molecular Pharmaceutics, 6(2), 634–640. https://doi.org/10.1021/mp8002368

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free